Global Cord Blood Corp (NYSE:CO) Short Interest Down 24.6% in August

Share on StockTwits

Global Cord Blood Corp (NYSE:CO) was the target of a significant decline in short interest in the month of August. As of August 15th, there was short interest totalling 260,700 shares, a decline of 24.6% from the July 15th total of 345,800 shares. Based on an average trading volume of 62,600 shares, the days-to-cover ratio is currently 4.2 days. Currently, 0.7% of the shares of the stock are sold short.

NYSE CO traded down $0.37 on Tuesday, reaching $4.60. The company’s stock had a trading volume of 227,820 shares, compared to its average volume of 63,949. The firm has a market cap of $670.96 million, a PE ratio of 15.77 and a beta of 0.20. The business has a 50-day moving average price of $5.62 and a 200 day moving average price of $6.42. Global Cord Blood has a 52 week low of $4.25 and a 52 week high of $7.73.

Global Cord Blood (NYSE:CO) last issued its quarterly earnings data on Tuesday, June 18th. The medical research company reported $0.11 earnings per share for the quarter. The firm had revenue of $37.50 million for the quarter. Global Cord Blood had a net margin of 29.56% and a return on equity of 8.84%.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in shares of Global Cord Blood by 2,935.0% during the fourth quarter. BlackRock Inc. now owns 7,284 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 7,044 shares during the last quarter. Lingohr & Partner Asset Management GmbH acquired a new position in Global Cord Blood in the first quarter valued at approximately $422,000. Parametric Portfolio Associates LLC lifted its holdings in Global Cord Blood by 20.3% in the second quarter. Parametric Portfolio Associates LLC now owns 94,469 shares of the medical research company’s stock valued at $546,000 after buying an additional 15,934 shares during the period. SG Americas Securities LLC acquired a new stake in Global Cord Blood in the first quarter worth $758,000. Finally, Quinn Opportunity Partners LLC raised its holdings in Global Cord Blood by 2.3% in the second quarter. Quinn Opportunity Partners LLC now owns 259,764 shares of the medical research company’s stock worth $1,501,000 after purchasing an additional 5,800 shares during the period. 16.94% of the stock is currently owned by institutional investors and hedge funds.

Global Cord Blood Company Profile

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services.

Recommended Story: Return on Investment (ROI)

Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with's FREE daily email newsletter.